On Monday 15 May, the European Commission opened formal investigations into a possible abuse of dominant position by the South African company Aspen Pharma.
The institution's investigation will focus on the prices practised by the pharmaceutical company for five niche drugs treating cancer, particularly blood tumours. This is the first time that the Commission has investigated the pricing practices of the pharmaceutical industry.
Following the expiry of their patents, Aspen bought the...